

6 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| GT Venture III | September 2026 | Indefinite | $25M | 2 |
| GT Private Equity XII | February 2026 | $250M | $8.7M | 13 |
| GT Private Equity XI | April 2023 | $250M | $180M | 193 |
| GT Windward I | 2023 | Indefinite | $53M | 2 |
| GT Real Assets IV | October 2022 | $75M | $46M | 78 |
| GT Venture II | 2022 | $75M | $16M | 8 |
| GT Private Equity X-A | April 2021 | $200M | $88M | 97 |
| GT Private Equity X | April 2021 | $200M | $33M | 38 |
| GT Venture | February 2021 | $75M | $19M | 10 |
| GT Credit Opportunity Fund | August 2020 | Indefinite | $92M | 85 |
| GT Biotech Fund | April 2020 | Indefinite | $234M | 314 |
| GT Real Assets III | July 2019 | $125M | $59M | 63 |
| GT Special Opportunities III-A | 2019 | Indefinite | $63M | 52 |
| Palladian Partners IX | February 2018 | $250M | $11M | 8 |
| Palladian Partners IX-A | February 2018 | $250M | $20M | 5 |
| GT Insurance II | April 2017 | Indefinite | $21M | 1 |
| GT ILS Fund | 2017 | Indefinite | $229M | 108 |
| GT Real Assets II | August 2015 | $150M | $54M | 76 |
| GT Institutional Fixed Income Fund | 2015 | Indefinite | $79M | 39 |
| GT Insurance | 2015 | Indefinite | $38M | 3 |
| Palladian Partners VIII | June 2014 | $250M | $89M | 171 |
| Palladian Partners VIII-A | June 2014 | $250M | $58M | 97 |
| GT Special Opportunities III | July 2011 | Indefinite | $199M | 261 |
| GT Special Opportunities II | July 2009 | Indefinite | $24M | 53 |
| GT MLP FUND | August 2008 | Indefinite | $82M | 185 |
| GT EMERGING MARKETS L P | November 2006 | Indefinite | $141M | 110 |
| GT KOREA | October 2006 | Indefinite | $18M | 4 |
| GT International Equity Fund | August 2006 | Indefinite | $144M | 107 |
| GT U.S. Fund | August 2006 | Indefinite | $133M | 92 |
| GT Fixed Income Fund | October 2004 | Indefinite | $73M | 95 |
| GT ERISA FUND | 2004 | Indefinite | $578M | 456 |
| GT GLOBAL OPPORTUNITIES II | 2001 | Indefinite | $25M | 1 |
| GT Offshore Fund | 2001 | Indefinite | $3B | 770 |
| GT GLOBAL OPPORTUNITIES | October 2000 | Indefinite | $139M | 6 |
| GT International Equity QP Fund | July 2000 | Indefinite | $808M | 384 |
| GT U.S. QP Fund | July 2000 | Indefinite | $468M | 249 |
| GT INSTITUTIONAL INVESTORS | July 1997 | Indefinite | $40M | 55 |
| GT ASSET ALLOCATION FUND | 1995 | Indefinite | $398M | 172 |
| GT Global Hedge | July 1994 | Indefinite | $3.2B | 1,023 |
| GT Emerging Markets (QP) | October 1992 | Indefinite | $489M | 467 |
| GT Partners | 1991 | Indefinite | $5.5B | 1,413 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
16 partners are named across this firm’s filings, 6 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Andrew ChapmanNot on the current fund | Quiet | None listed | 1 | 0 |
| Charles GerberNot on the current fund | Quiet | Fintech | 1 | 0 |
| Darren Kearns | Quiet | None listed | 0 | 0 |
| David EastNot on the current fund | Quiet | None listed | 0 | 0 |
| Ernest MorrisonNot on the current fund | Quiet | None listed | 0 | 0 |
| Justin Rikard | Quiet | None listed | 0 | 0 |
| Kojo McLennonNot on the current fund | Quiet | None listed | 0 | 0 |
| Mary Cornpropst | Quiet | None listed | 0 | 0 |
| Michael Douglass | Quiet | None listed | 0 | 0 |
| Nicholas LaneNot on the current fund | Quiet | None listed | 0 | 0 |
| Robert TaylorNot on the current fund | Quiet | Biotech & pharma, AI & machine learning, Climate & energy | 15 | 0 |
| Ryan Gibbs | Quiet | None listed | 0 | 0 |
| Simone Meeks | Quiet | None listed | 0 | 0 |
| Simonev MeeksNot on the current fund | Quiet | None listed | 0 | 0 |
| William PickensNot on the current fund | Quiet | None listed | 0 | 0 |
| William RyanNot on the current fund | Quiet | Medical devices, Biotech & pharma, Logistics & supply chain | 4 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Categories of GT Venture’s own portfolio companies, based on 15 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of GT Venture’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Luma Group | 4 | Beech Tree Labs, OrthoAccel Technologies, Parlytix, Synaptive Medical |
| 5AM Ventures | 1 | Precision Nanosystems |
| Clean Energy Ventures | 1 | REsurety |
| Excelerate Health Ventures | 1 | Precision Nanosystems |
| RSCM | 1 | MCE Social Capital |
| Silverton Partners | 1 | Convey |
| Techstars Ventures | 1 | Convey |
| Valor Siren Ventures | 1 | Velocity Holding Company |
| Westlake Biopartners | 1 | Precision Nanosystems |
A shared board seat: a company where filings name a GT Venture partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.